205 related articles for article (PubMed ID: 9772721)
1. Assessment of the activity of atovaquone-loaded nanocapsules in the treatment of acute and chronic murine toxoplasmosis.
Sordet F; Aumjaud Y; Fessi H; Derouin F
Parasite; 1998 Sep; 5(3):223-9. PubMed ID: 9772721
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of atovaquone and sulfadiazine in the treatment of mice infected with Toxoplasma gondii strains isolated in Brazil.
Alves CF; Vitor RW
Parasite; 2005 Jun; 12(2):171-7. PubMed ID: 15991831
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo effects of rifabutin alone or combined with atovaquone against Toxoplasma gondii.
Romand S; Della Bruna C; Farinotti R; Derouin F
Antimicrob Agents Chemother; 1996 Sep; 40(9):2015-20. PubMed ID: 8878573
[TBL] [Abstract][Full Text] [Related]
4. Stage conversion of Toxoplasma gondii RH parasites in mice by treatment with atovaquone and pyrrolidine dithiocarbamate.
Djurković-Djaković O; Nikolić A; Bobić B; Klun I; Aleksić A
Microbes Infect; 2005 Jan; 7(1):49-54. PubMed ID: 15716077
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo activities of the hydroxynaphthoquinone atovaquone alone or combined with pyrimethamine, sulfadiazine, clarithromycin, or minocycline against Toxoplasma gondii.
Romand S; Pudney M; Derouin F
Antimicrob Agents Chemother; 1993 Nov; 37(11):2371-8. PubMed ID: 8285620
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of atovaquone combined with clindamycin against murine infection with a cystogenic (Me49) strain of Toxoplasma gondii.
Djurković-Djaković O; Milenković V; Nikolić A; Bobić B; Grujić J
J Antimicrob Chemother; 2002 Dec; 50(6):981-7. PubMed ID: 12461021
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the efficacy of atovaquone alone or in combination with azithromycin against acute murine toxoplasmosis.
Moshkani SK; Dalimi A
Vet Res Commun; 2000 Apr; 24(3):169-77. PubMed ID: 10836275
[TBL] [Abstract][Full Text] [Related]
8. An ultrastructural study of the effect of treatment with atovaquone in brains of mice chronically infected with the ME49 strain of Toxoplasma gondii.
Ferguson DJ; Huskinson-Mark J; Araujo FG; Remington JS
Int J Exp Pathol; 1994 Apr; 75(2):111-6. PubMed ID: 8199003
[TBL] [Abstract][Full Text] [Related]
9. Activity of natural and synthetic naphthoquinones against Toxoplasma gondii, in vitro and in murine models of infection.
Ferreira RA; Oliveira AB; Gualberto SA; Vitor RW
Parasite; 2002 Sep; 9(3):261-9. PubMed ID: 12375370
[TBL] [Abstract][Full Text] [Related]
10. Synergistic effect of clindamycin and atovaquone in acute murine toxoplasmosis.
Djurković-Djaković O; Nikolić T; Robert-Gangneux F; Bobić B; Nikolić A
Antimicrob Agents Chemother; 1999 Sep; 43(9):2240-4. PubMed ID: 10471572
[TBL] [Abstract][Full Text] [Related]
11. Combined effect of atovaquone and pyrrolidine dithiocarbamate in the treatment of acute murine toxoplasmosis.
Djurković-Djaković O; Nikolić A; Bobić B; Klun I
Chemotherapy; 2004 Jun; 50(3):155-6. PubMed ID: 15272229
[No Abstract] [Full Text] [Related]
12. Atovaquone nanosuspensions show excellent therapeutic effect in a new murine model of reactivated toxoplasmosis.
Schöler N; Krause K; Kayser O; Müller RH; Borner K; Hahn H; Liesenfeld O
Antimicrob Agents Chemother; 2001 Jun; 45(6):1771-9. PubMed ID: 11353624
[TBL] [Abstract][Full Text] [Related]
13. Could miltefosine be used as a therapy for toxoplasmosis?
Eissa MM; Barakat AM; Amer EI; Younis LK
Exp Parasitol; 2015 Oct; 157():12-22. PubMed ID: 26112396
[TBL] [Abstract][Full Text] [Related]
14. SDS-coated atovaquone nanosuspensions show improved therapeutic efficacy against experimental acquired and reactivated toxoplasmosis by improving passage of gastrointestinal and blood-brain barriers.
Shubar HM; Lachenmaier S; Heimesaat MM; Lohman U; Mauludin R; Mueller RH; Fitzner R; Borner K; Liesenfeld O
J Drug Target; 2011 Feb; 19(2):114-24. PubMed ID: 20367080
[TBL] [Abstract][Full Text] [Related]
15. The activity of atovaquone (566C80) in murine toxoplasmosis is markedly augmented when used in combination with pyrimethamine or sulfadiazine.
Araujo FG; Lin T; Remington JS
J Infect Dis; 1993 Feb; 167(2):494-7. PubMed ID: 8421189
[TBL] [Abstract][Full Text] [Related]
16. Use of ketolides in combination with other drugs to treat experimental toxoplasmosis.
Araujo FG; Khan AA; Bryskier A; Remington JS
J Antimicrob Chemother; 1998 Nov; 42(5):665-7. PubMed ID: 9848454
[TBL] [Abstract][Full Text] [Related]
17. Remarkable in vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against tachyzoites and tissue cysts of Toxoplasma gondii.
Araujo FG; Huskinson J; Remington JS
Antimicrob Agents Chemother; 1991 Feb; 35(2):293-9. PubMed ID: 2024964
[TBL] [Abstract][Full Text] [Related]
18. [Effects of atovaquone and astragalus combination on the treatment and IL-2, IL-12, IFN-γ levels on mouse models of acute toxoplasmosis].
Sönmez N; Büyükbaba Boral O; Kaşali K; Tekeli F
Mikrobiyol Bul; 2014 Oct; 48(4):639-51. PubMed ID: 25492659
[TBL] [Abstract][Full Text] [Related]
19. Histopathological and ultrastructural assessment of atovaquone-proguanil hydrochloride combination in chronic murine toxoplasmosis.
Elmehankar MS; Elhenawy AA; Aboukamar WA; Elzoheiry MA; Nabih N
Ultrastruct Pathol; 2021 Nov; 45(6):376-383. PubMed ID: 34595988
[TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against the cyst form of Toxoplasma gondii.
Araujo FG; Huskinson-Mark J; Gutteridge WE; Remington JS
Antimicrob Agents Chemother; 1992 Feb; 36(2):326-30. PubMed ID: 1605598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
